Director/PDMR Shareholding
November 18 2009 - 11:37AM
UK Regulatory
TIDMHIK
RNS Number : 7262C
Hikma Pharmaceuticals Plc
18 November 2009
Annex DTR3
Notification of Transactions of Directors/Persons Discharging Managerial
Responsibility and Connected Persons
All relevant boxes should be completed in block capital letters
+-----+--------------------------------+----+--------------------------------+
| | Name of the Issuer: | | State whether the notification |
| | Hikma Pharmaceuticals PLC | | relates to (i) a transaction |
| | | | notified in accordance with |
| | | | DTR 3.1.2 R, (ii) a disclosure |
| | | | made in accordance with LR |
| | | | 9.8.6R(1) or (iii) a |
| | | | disclosure made in accordance |
| | | | with section 793 of the |
| | | | Companies Act (2006): |
| | | | DTR 3.1.2 R |
+-----+--------------------------------+----+--------------------------------+
| | Name of person discharging | | State whether notification |
| | managerial | | relates to a person connected |
| | responsibilities/director: | | with a person discharging |
| | Samih Darwazah, Said Darwazah, | | managerial responsibilities/ |
| | Mazen Darwazah and Ali | | director named in 3 and |
| | Al-Husry | | identify the connected person: |
| | | | Yes: Darhold Limited |
+-----+--------------------------------+----+--------------------------------+
| | Indicate whether the | | Description of shares |
| | notification is in respect of | | (including class), debentures |
| | a holding of the person | | or derivatives or financial |
| | referred to in 3 or 4 above or | | instruments relating to |
| | in respect of a non-beneficial | | shares: |
| | interest: | | Ordinary Shares |
| | Beneficial interest Darhold | | |
| | Limited | | |
+-----+--------------------------------+----+--------------------------------+
| | Name of registered | | State the nature of the |
| | shareholders(s) and, if more | | transaction: |
| | than one, the number of shares | | A pledge over 11,500,000 |
| | held by each of them: | | Ordinary Shares in support of |
| | Clearstream account for and on | | a loan |
| | behalf of Europe Arab Bank plc | | |
+-----+--------------------------------+----+--------------------------------+
| | Number of shares, debentures | | Percentage of issued class |
| | or financial instruments | | acquired (treasury shares of |
| | relating to shares acquired: | | that class should not be taken |
| | None | | into account when calculating |
| | | | percentage): |
| | | | N/A |
+-----+--------------------------------+----+--------------------------------+
| | Number of shares, debentures | | Percentage of issued class |
| | or financial instruments | | disposed (treasury shares of |
| | relating to shares disposed: | | that class should not be taken |
| | None | | into account when calculating |
| | | | percentage): |
| | | | N/A |
+-----+--------------------------------+----+--------------------------------+
| | Price per share or value of | | Date and place of transaction: |
| | transaction: | | London, 16 November 2009 |
| | N/A | | |
+-----+--------------------------------+----+--------------------------------+
| | Total holding following | | Date issuer informed of |
| | notification and total | | transaction: |
| | percentage holding following | | 18 November 2009 |
| | notification (any treasury | | |
| | shares should not be taken | | |
| | into account when calculating | | |
| | percentage): | | |
| | 57,183,028 - 29.9 per cent. | | |
+-----+--------------------------------+----+--------------------------------+
+---------+-----------------------------+----+--------------------------------+
| If a person discharging managerial responsibilities has been granted |
| options by the issuer complete the following boxes |
+-----------------------------------------------------------------------------+
| | Date of grant | | Period during which or date on |
| | | | which exercisable |
+---------+-----------------------------+----+--------------------------------+
| | Total amount paid (if any) | | Description of shares or |
| | for grant of the option | | debentures involved (class and |
| | | | number) |
+---------+-----------------------------+----+--------------------------------+
| | Exercise price (if fixed at | | Total number of shares or |
| | time of grant) or | | debentures over which options |
| | indication that price is to | | held following notification |
| | be fixed at the time of | | |
| | exercise | | |
+---------+-----------------------------+----+--------------------------------+
| | Any additional information | | Name of contact and telephone |
| | | | number for queries |
+---------+-----------------------------+----+--------------------------------+
+--------------------------------------------------------------------------+
| Name of authorised official or issuer responsible for making |
| notification: Henry Knowles |
+--------------------------------------------------------------------------+
| Date of notification 18 November 2009 |
+--------------------------------------------------------------------------+
Notes:
This form is intended for use by an issuer to make a RIS notification required
by DTR 3.1.4
(1)An issuer making a notification in respect of a transaction relating to the
shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.
(2) An issuer making a notification in respect of a derivative relating the
shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.
(3) An issuer making a notification in respect of options granted to a
director/person discharging managerial responsibilities should complete boxes 1
to 3 and 17 to 24.
(4) An issuer making a notification in respect of a financial instrument
relating to the shares of the issuer (other than a debenture) should complete
boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSBLBDBUXBGGCI
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024
